OTCMKTS:MAQAF Atlas Arteria (MAQAF) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free MAQAF Stock Alerts $3.41 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$3.41▼$3.4150-Day Range$3.17▼$3.7552-Week Range$3.17▼$4.56VolumeN/AAverage Volume3,636 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield2.43%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Atlas Arteria alerts: Email Address Ad Whats On FinancePutin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. Click to kickstart your journey to survive in the new economy About Atlas Arteria Stock (OTCMKTS:MAQAF)Atlas Arteria Limited owns, develops, and operates toll roads. It holds a 31.14% of interest in the APRR and A79 and 31.17% interest in the ADELAC located in France; 100% interest in the Warnow Tunnel located in Rostock, Germany; 66.67% interest in the Chicago Skyway situated in Chicago and 100% interest in the Dulles Greenway located in Virginia, United States. The company was formerly known as Macquarie Atlas Roads Limited and changed its name to Atlas Arteria Limited in May 2018. Atlas Arteria Limited was incorporated in 2009 and is based in Melbourne, Australia.Read More MAQAF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MAQAF Stock News HeadlinesMarch 25, 2024 | finance.yahoo.comAtlas Arteria Ltd's Dividend AnalysisFebruary 29, 2024 | finance.yahoo.comAtlas Arteria Full Year 2023 Earnings: EPS: AU$0.22 (vs AU$0.25 in FY 2022)April 23, 2024 | The Bull Report (Ad)Healthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.February 7, 2024 | afr.comAtlas Arteria’s 40pc Washington DC toll rise proposal hits dead endJanuary 31, 2024 | markets.businessinsider.comMacquarie Reaffirms Their Hold Rating on Atlas Arteria (MAQAF)December 16, 2023 | finance.yahoo.comWith 78% ownership of the shares, Atlas Arteria Limited (ASX:ALX) is heavily dominated by institutional ownersNovember 8, 2023 | morningstar.comAtlas Arteria Ltd MAQAFNovember 7, 2023 | afr.comIFM Investors creeps up Atlas Arteria’s register; Jarden on ticketApril 23, 2024 | The Bull Report (Ad)Healthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.October 3, 2023 | markets.businessinsider.comAtlas Arteria (MAQAF) Receives a Hold from RBC CapitalSeptember 27, 2023 | afr.comAtlas Arteria to fight new French motorway taxesSeptember 26, 2023 | finance.yahoo.comBullish Atlas Arteria Insiders Loaded Up On AU$1.3m Of StockSeptember 7, 2023 | finance.yahoo.comMAQAF - Atlas Arteria LimitedSeptember 1, 2023 | markets.businessinsider.comRBC Capital Sticks to Its Hold Rating for Atlas Arteria (MAQAF)July 4, 2023 | markets.businessinsider.comRBC Capital Sticks to Their Hold Rating for Atlas Arteria (MAQAF)June 17, 2023 | finance.yahoo.comWith 80% ownership of the shares, Atlas Arteria Limited (ASX:ALX) is heavily dominated by institutional ownersMay 30, 2023 | afr.com$9b tollroads group Atlas Arteria hit with first strikeMay 3, 2023 | afr.comIFM Investors creeps up at Atlas Arteria, Jarden trades $197m lineFebruary 27, 2023 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Atlas Arteria (MAQAF)February 24, 2023 | finance.yahoo.comAtlas Arteria Full Year 2022 Earnings: Misses ExpectationsFebruary 23, 2023 | afr.comAtlas Arteria to bypass EastLink saleFebruary 22, 2023 | afr.comAtlas Arteria’s annual profits jump 47pc on traffic reboundJanuary 29, 2023 | markets.businessinsider.comABN Amro Reaffirms Their Hold Rating on Atlas Arteria (MAQAF)January 7, 2023 | finance.yahoo.comWith 81% ownership of the shares, Atlas Arteria Limited (ASX:ALX) is heavily dominated by institutional ownersDecember 19, 2022 | afr.comIFM adviser Ken Daley to join Atlas Arteria boardNovember 24, 2022 | markets.businessinsider.comPositive Report for Atlas Arteria (MAQAF) from RBC CapitalOctober 16, 2022 | afr.comAtlas Arteria stock back in play after $3b equity raiseSee More Headlines Receive MAQAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atlas Arteria and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorIndustrials Industry Infrastructure Operations Sub-IndustryN/A Current SymbolOTCMKTS:MAQAF CUSIPN/A CIKN/A Webwww.atlasarteria.com Phone611800621694FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Graeme Francis Bevans (Age 66)MD, CEO & Executive Director Comp: $1.8MMr. David CollinsChief Financial OfficerMr. Vincent Portal-BarraultChief Operating OfficerTess PalmerDirector of Investor RelationsMr. Clayton John McCormack B.Com.L.L.B., Company Secretary & General CounselNavleen PrasadPublic Affairs ManagerJim DicksonCorporate Development & Strategy ExecutiveMs. Catherine BrainGroup Executive of People & CultureMr. Paul Lynch B.Com.L.L.B., Joint Company SecretaryMr. Ryan Reynolds C.F.A.Specialist of Forecasting and AnalysisMore ExecutivesKey CompetitorsFerrovialOTCMKTS:FERVFPARK24OTCMKTS:PKCOYPromotora y Operadora de Infraestructura, S. A. B. de C. V.OTCMKTS:PYOIFPromotora y Operadora de Infraestructura, S. A. B. de C. V.OTCMKTS:PUODYTransurban GroupOTCMKTS:TRAUFView All Competitors MAQAF Stock Analysis - Frequently Asked Questions Should I buy or sell Atlas Arteria stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atlas Arteria in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MAQAF shares. View MAQAF analyst ratings or view top-rated stocks. How have MAQAF shares performed in 2024? Atlas Arteria's stock was trading at $3.95 at the beginning of 2024. Since then, MAQAF shares have decreased by 13.7% and is now trading at $3.41. View the best growth stocks for 2024 here. Is Atlas Arteria a good dividend stock? Atlas Arteria (OTCMKTS:MAQAF) pays an annual dividend of $0.08 per share and currently has a dividend yield of 5.02%. MAQAF has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. How do I buy shares of Atlas Arteria? Shares of MAQAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MAQAF) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atlas Arteria Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
